Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy

被引：0
|
作者：
Sestak, Ivana
Regan, Meredith
Dodson, Andrew
Viale, Giuseppe
Thurlimann, Beat
Colleoni, Marco
Cuzick, Jack
Dowsett, Mitch
机构：
[1] QMUL, Wolfson Inst Prevent Med, Ctr Canc Prevent, London, England
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ralph Lauren Ctr Breast Canc Res, London, England
[4] European Inst Oncol, Milan, Italy
[5] Kantonsspital St Gallen, St Gallen, Switzerland
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS6-01
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
    Koji Takada
    Shinichiro Kashiwagi
    Yuka Asano
    Wataru Goto
    Rika Kouhashi
    Akimichi Yabumoto
    Sae Ishihara
    Tamami Morisaki
    Masatsune Shibutani
    Hiroaki Tanaka
    Kosei Hirakawa
    Masaichi Ohira
    BMC Women's Health, 21
  • [42] Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
    Li, Li
    Chang, Bingmei
    Jiang, Xiaoyue
    Fan, Xueke
    Li, Yingrui
    Li, Teng
    Wu, Shanshan
    Zhang, Jun
    Kariminia, Seyed
    Li, Qin
    BMC CANCER, 2018, 18
  • [43] Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
    Li Li
    Bingmei Chang
    Xiaoyue Jiang
    Xueke Fan
    Yingrui Li
    Teng Li
    Shanshan Wu
    Jun Zhang
    Seyed Kariminia
    Qin Li
    BMC Cancer, 18
  • [44] Risk of recurrence following 5 years of adjuvant hormone therapy for hormone receptor positive early breast cancer.
    Lohrisch, C.
    Speers, C.
    Chia, S.
    Kennecke, H.
    Ellard, S.
    Tyldesley, S.
    CANCER RESEARCH, 2013, 73
  • [45] Endocrine therapy alone as primary treatment for elderly patients with clinical stage I to III estrogen receptor positive breast cancer with low recurrence score
    Aft, R.
    Trinkaus, K.
    Ma, C.
    CANCER RESEARCH, 2016, 76
  • [46] Pathologic response to neoadjuvant therapy in HER2 positive/oestrogen receptor positive breast cancer patients
    Gasol Cudos, A.
    Morales, S.
    Rodriguez Galindo, A.
    Velasco Sanchez, A.
    Serrate Lopez, A.
    Mele Olive, J.
    Canosa Morales, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S333 - S333
  • [47] Morphological and Molecular Changes of Oestrogen Receptor Positive Breast Cancer Following Bridging Endocrine Therapy: A UK Multicentre Study
    Miligy, I
    Awasthi, R.
    Mir, Y.
    Khurana, A.
    Sharma, V
    Chandaran, U.
    Rakha, E.
    Maurice, Y.
    Kearns, D.
    Oweis, R.
    Asar, A.
    Ironside, A.
    Shaaban, A.
    JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1): : S21 - S21
  • [48] Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy
    Algorashi, Ibrahim
    Goldvaser, Hadar
    Ribnikar, Domen
    Cescon, David W.
    Amir, Eitan
    CANCER TREATMENT REVIEWS, 2018, 70 : 138 - 143
  • [49] Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy
    Algorashi, I.
    Eitan, E.
    Goldvaser, H.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S11 - S11
  • [50] Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
    Zhang, Yi
    Schnabel, Catherine A.
    Schroeder, Brock E.
    Jerevall, Piiha-Lotta
    Jankowitz, Rachel C.
    Fornander, Tommy
    Stal, Olle
    Brufsky, Adam M.
    Sgroi, Dennis
    Erlander, Mark G.
    CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4196 - 4205
12345